Exomics and immunogenics: Bridging mutational load and immune checkpoints efficacy

Anti-PD-1/PD-L1 antibodies are emerging as promising anticancer therapeutics. Interestingly, elevated response rates to these agents are mostly documented among patients with tumors that bear high level of somatic mutations, like melanoma or non-small cell lung carcinoma. We herein formulate the hyp...

Descripción completa

Detalles Bibliográficos
Autores principales: Champiat, Stéphane, Ferté, Charles, Lebel-Binay, Sophie, Eggermont, Alexander, Soria, Jean Charles
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Landes Bioscience 2014
Materias:
Point of View
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3937193/
https://www.ncbi.nlm.nih.gov/pubmed/24605269
http://dx.doi.org/10.4161/onci.27817

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3937193/
https://www.ncbi.nlm.nih.gov/pubmed/24605269
http://dx.doi.org/10.4161/onci.27817

Ejemplares similares